Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

275 Views

Poster Session: COVID-19: Treatment

1141 - Phase 3 Trial (in progress) of the SYK inhibitor Fostamatinib in Patients Hospitalized with COVID-19: Protocol and Study Implementation Updates

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Presenting Author(s)

LY

Lucy Yan, MD, PhD (he/him/his)

VP, Clinical Development
Rigel Pharmaceuticals
South San Francisco, California, United States

Co-Author(s)

Ziad Mallat, MD, PhD

Professor of Cardiovascular Medicine
University of Cambridge
Cambridge, England, United Kingdom
SL

Suzana Margareth Lobo, MD, PhD

Hospital de Base - FAMERP
São José do Rio Preto, Sao Paulo, Brazil
AM

Anuj Malik, MD, MS

Ascension St. John's Medical Center
Tulsa, Oklahoma, United States
WD

Wolfgang Dummer, MD, PhD

Rigel Pharmaceuticals
South San Francisco, California, United States